Activest Wealth Management’s Grace Therapeutics GRCE Stock Holding History

Activest Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$224	Hold	104	–	–	﹤0.01%	965
2026 Q2	$236	Hold	104	–	–	﹤0.01%	1146
2026 Q1	$482	Hold	104	–	–	﹤0.01%	1077
2025 Q4	$360	Hold	104	–	–	﹤0.01%	1016
2025 Q3	$310	Hold	104	–	–	﹤0.01%	996
2025 Q2	$309	Hold	104	–	–	﹤0.01%	928
2025 Q1	$237	Hold	104	–	–	﹤0.01%	926
2024 Q4	$389	Hold	104	–	–	﹤0.01%	561
2024 Q3	$312	Hold	104	–	–	﹤0.01%	502
2024 Q2	$304	Buy	+104	New	+$314	﹤0.01%	477

Other funds holding GRCE

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Activest Wealth Management's GRCE Position: Q3 2026 in Review

Activest Wealth Management held its Grace Therapeutics (GRCE) position steady in Q3 2026 at 104 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Activest Wealth Management first reported a position in GRCE in Q2 2024 and has held it in 10 quarters since. The position peaked at $482 in Q1 2026. 6 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

Activest Wealth Management held 104 shares of Grace Therapeutics worth $224 as of Q3 2026.
Activest Wealth Management left its Grace Therapeutics share count unchanged in Q3 2026.
Grace Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #965 holding.
Activest Wealth Management first reported a position in Grace Therapeutics in Q2 2024 and has held it in 10 quarters since.
Activest Wealth Management's Grace Therapeutics position peaked at $482 in Q1 2026.
6 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.